Prospects for Treatment of Pediatric Vitreoretinal Diseases with Vascular Endothelial Growth Factor Inhibition

Seminars in Ophthalmology

Volumn 24, Issue 2, 2009, Pages 70-76

  Lin, Kristie L ^a,b   Hirose, Tatsuo ^a   Kroll, Arnold J ^a   Lou, Peter L ^a   Ryan, Edward A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Zero Longfellow Place ^*  (United States)

Author keywords

Anti angiogenesis; Anti VEGF and infants; Coats' disease; Familial exudative vitreoretinopathy; Intravitreal avastin; Pediatric vitreoretinopathy; Retinopathy of incontinentia pigmenti; Retinopathy of prematurity; VEGF; VEGF Inhibition

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; TRIAMCINOLONE; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CRYOTHERAPY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; EXUDATIVE RETINITIS; FAMILIAL EXUDATIVE VITREORETINOPATHY; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; INCONTINENTIA PIGMENTI; LASER COAGULATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA BLOOD VESSEL; RETROLENTAL FIBROPLASIA; REVIEW; SIDE EFFECT; SUDDEN DEATH; TREATMENT OUTCOME; VISUAL ACUITY; VITREORETINOPATHY; CASE REPORT; CONGENITAL MALFORMATION; DRUG ANTAGONISM; EYE; EYE DISEASE; INFANT; MALE; NEOVASCULARIZATION (PATHOLOGY); NEWBORN; PREOPERATIVE CARE; RETINA DETACHMENT; RETINA DISEASE; VASCULARIZATION; VITREOUS BODY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; EYE; EYE DISEASES; HUMANS; INCONTINENTIA PIGMENTI; INFANT; INFANT, NEWBORN; MALE; NEOVASCULARIZATION, PATHOLOGIC; PREOPERATIVE CARE; RETINAL DETACHMENT; RETINAL DISEASES; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 66149113732     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.1080/08820530902800108     Document Type: Review

References (36)

1. Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: Roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci 2000;41:1217-1228.
2. Bhisitkul RB. Vascular endothelial growth factor biology: Clinical implications for ocular treatments. Br J Ophthalmol 2006;90:1542-1547.
3. Gordon JD, Mesiano S, Zaloudek CJ, Jaffe RB. Vascular endothelial growth factor localization in human ovary and fallopian tubes: Possible role in reproductive function and ovarian cyst formation. J Clin Endocrinol Metab 1996;81:353-359.
4. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983- 985.
5. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-1309.
6. Bates DO, Harper SJ. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 2002;39:225-237.
7. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
8. Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, Rowan A, Yan Z, Campochiaro PA, Semenza GL. Cell type-specific regulationof angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res 2003;93:1074-1081.
9. Vinores SA, Youssri AL, Luna JD. Upregulation of vascular endothelial growth factor in ischemic and no-ischemic human and experimental retinal disease. Histol Histopathol 1997;12:99- 109.
10. Bates DO, Harper SJ. Therapeutic potential of inhibitory VEGF splice variants. Future Oncol 2005;1:467-73.
11. Palmer EA, Phelps DL, Spencer R, Lutty GA. Retinopathy of prematurity. In Ryan S, ed. Retina, Philadelphia, PA: Elsevier-Mosby, 2006;1447-1474.
12. Penn JS, Tolman BL, Lowery LA. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthalmol Vis Sci 1993;34:576-585.
13. Gu X, El-Remessy AB, Brooks SE, Al-Shabrawey M, Tsai NT, Caldwell RB. Hyperoxia induces retinal vascular endothelial cell apoptosis through formation of peroxynitrite. Am J Physiol Cell Physiol 2003;285:546-554.
14. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024-1028.
15. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothe-lial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996;114:1219-1228.
16. Lashkari K, Hirose T, Yazdany J, McMeel JW, Kazlauskas A, Rahimi N. Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol 2000;156:1337-1344.
17. SonmezK,Drenser KA, CaponeA Jr, Trese MT. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 2008;115:1065-1070.
18. Quiroz-Mercado H, Martinez-Castellanos M, Hernandez-Rojas M, Salazar-Teran N, Chan P. Antiangiogenic therapy with in-travitreal bevacizumab for retinopathy of prematurity. Retina 2008;28:S19-S25.
19. Mintz-Hittner HA, Kuffel RR Jr. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina 2008 Jun;28(6):831-838.
20. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-439.
21. Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chévez-Barrios P. Intravitreous bevacizumab as anti-vascular en-dothelial growth factor therapy for retinopathy of prematurity: A morphologic study. Arch Ophthalmol 2008;126:1161- 1163.
22. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharma-cokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859.
23. Konopatskaya O, Churchill AJ, Harper SJ, Bates DO, Gardiner TA. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol Vis 2006;12:626-632.
24. Quiram PA, Drenser KA, Lai MM, Capone A, Trese MT. Treatment of vascularly active familial exudative vitreoretinopathy with pegaptanib sodium (Macugen). Retina 2008;28:S8-S12.
25. Criswick VG, Schepens CL. Familial exudative vitreoretinopathy. Am J Ophthalmol 1969;68:578-594.
26. Zhou S, Overbeek PA. Elevated TGF beta signaling inhibited ocular vascular development. Dev Biol 2001;237:45-53.
27. Parmalee NL, Kitajewski J.Wnt signaling in angiogenesis. Curr Drug Targets 2008 Jul;9(7):558-564.
28. Zerlin M, Julius MA, Kitajewski J.Wnt/Frizzled signaling in angiogenesis. Angiogenesis 2008;11:63-69.
29. Honda S, Hirabayashi H, Tsukahara Y, Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 2008;246:1061- 1063.
30. Tagami M, Kusuhara S, Honda S, Tsukahara Y, Negi A. Rapid regression of retinal hemorrhage and neovascularization in a case of familial exudative vitreoretinopathy treated with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:1787-1789.
31. Do D, Haller J. Coats disease. In Ryan S, ed. Retina. Philadelphia, PA: Elsevier-Mosby, 2006;1417-1423.
32. Quiroz-Mercado H, Ustariz-González O, Martinez-Castellanos MA, Covarrubias P, Dominguez F, Sanchez-Huerta V. Our experience after 1765 intravitreal injections of bevacizumab: The importance of being part of a developing story. Semin Ophthalmol 2007 Apr-Jun;22(2):109-125.
33. Jun JH, Kim YC, Kim KS. Resolution of severe macular edema in adult coats' disease with intravitreal triamcinolone and bevacizumab injection. Korean J Ophthalmol 2008;22:190- 193.
34. Cakir M, Cekiç O, Yilmaz OF. Combined intravitreal bevacizumab and triamcinolone injection in a child with Coats disease. J AAPOS 2008;12:309-311.
35. Meir P, Wiedermann P. Surgical aspects of vitreoretinal diseases in children. In Ryan S, ed. Retina. Philadelphia, PA: Elsevier-Mosby, 2006;2494-2495.
36. Saint-GeniezM,Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D'Amore PA. Endogenous VEGF is required for visual function: Evidence for a survival role on müller cells and photoreceptors. PLoS ONE 2008;3(11):e3554.